CN104507491A - 胸腺素α在治疗化脓性鼻窦炎中的应用 - Google Patents

胸腺素α在治疗化脓性鼻窦炎中的应用 Download PDF

Info

Publication number
CN104507491A
CN104507491A CN201380022804.5A CN201380022804A CN104507491A CN 104507491 A CN104507491 A CN 104507491A CN 201380022804 A CN201380022804 A CN 201380022804A CN 104507491 A CN104507491 A CN 104507491A
Authority
CN
China
Prior art keywords
thymosin
method described
experimenter
aforementioned arbitrary
polarization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380022804.5A
Other languages
English (en)
Chinese (zh)
Inventor
H·A·德雷克斯哈吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of CN104507491A publication Critical patent/CN104507491A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201380022804.5A 2012-03-08 2013-03-08 胸腺素α在治疗化脓性鼻窦炎中的应用 Pending CN104507491A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608427P 2012-03-08 2012-03-08
US61/608,427 2012-03-08
PCT/US2013/029929 WO2013134666A1 (en) 2012-03-08 2013-03-08 Use of thymosin alpha for treatment of purulent rhinosinusitis

Publications (1)

Publication Number Publication Date
CN104507491A true CN104507491A (zh) 2015-04-08

Family

ID=49117390

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380022804.5A Pending CN104507491A (zh) 2012-03-08 2013-03-08 胸腺素α在治疗化脓性鼻窦炎中的应用

Country Status (8)

Country Link
US (1) US20150031617A1 (ja)
EP (1) EP2838551A4 (ja)
JP (1) JP2015510887A (ja)
KR (1) KR20150035495A (ja)
CN (1) CN104507491A (ja)
CA (1) CA2866159A1 (ja)
HK (1) HK1207008A1 (ja)
WO (1) WO2013134666A1 (ja)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1582163A (zh) * 2001-11-01 2005-02-16 赛克隆制药公司 胸腺素α1肽的给药方法
CN1777438A (zh) * 2003-04-23 2006-05-24 希克龙制药公司 用α胸腺肽治疗或预防呼吸病毒的感染
CN101244262A (zh) * 2007-02-14 2008-08-20 成都地奥九泓制药厂 一种治疗细菌性感染的药物联合药剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223601A1 (en) * 2002-04-12 2003-10-27 King's College London ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN Beta 4
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
US20100092499A1 (en) * 2004-12-06 2010-04-15 Sciclone Pharmaceuticals, Inc. Alpha Thymosin Peptides as Cancer Vaccine Adjuvants
CN101204578A (zh) * 2006-12-20 2008-06-25 干春玉 一种具有调节免疫、抗组织损伤及再生修复作用的胸腺素复合制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1582163A (zh) * 2001-11-01 2005-02-16 赛克隆制药公司 胸腺素α1肽的给药方法
US20100221274A1 (en) * 2001-11-01 2010-09-02 Sciclone Pharmaceuticals, Inc. Method of administering a thymosin alpha 1 peptide
CN1777438A (zh) * 2003-04-23 2006-05-24 希克龙制药公司 用α胸腺肽治疗或预防呼吸病毒的感染
CN101244262A (zh) * 2007-02-14 2008-08-20 成都地奥九泓制药厂 一种治疗细菌性感染的药物联合药剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M J A TAS 等: "Beneficial effects of the thymic hormone preparation thymoxtimulin in patients with defects in cell-mediated immunity and chronic purulent rhinosinusitis.A double-blind cross-over trial on improvements in monocyte polarization and clinical effects", 《CLINICAL&EXPERIMENTAL IMMUNOLOGY》 *
杨霞等: "胸腺肽α1体外刺激胃癌患者外周血单个核细胞对淋巴细胞亚群影响", 《第三军医大学学报》 *

Also Published As

Publication number Publication date
KR20150035495A (ko) 2015-04-06
EP2838551A1 (en) 2015-02-25
HK1207008A1 (en) 2016-01-22
EP2838551A4 (en) 2016-02-24
CA2866159A1 (en) 2013-09-12
US20150031617A1 (en) 2015-01-29
WO2013134666A1 (en) 2013-09-12
JP2015510887A (ja) 2015-04-13

Similar Documents

Publication Publication Date Title
Slaney et al. Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting
De Vita et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis
AU2020203867A1 (en) Cenicriviroc for the treatment of fibrosis
JP2018135370A (ja) 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
AU2011286486B9 (en) Drug and method for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including aids
JP2004515202A5 (ja)
CN110179989A (zh) 治疗狼疮的方法和组合物
CN109640959A (zh) 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
JP2019156854A (ja) 敗血症の処置のためのチモシンαの使用
JP2013535483A (ja) Ｐ２４タンパク質の産生を阻害するか又は排出を促進する医薬組成物及び方法
BRPI0924072B1 (pt) Anticorpos antivírus do herpes simples, seu método de produção, uso dos mesmos, ácido nucleico, vetor, célula hospedeira, método de produção da referida célula, bem como composição farmacêutica
Cameron New horizons in renal vasculitis
CN104507491A (zh) 胸腺素α在治疗化脓性鼻窦炎中的应用
CN111658636B (zh) 穿心莲内酯与地塞米松联用在制备复方抗急性淋巴细胞白血病药物中的应用
CN116440272B (zh) Gpvi抑制剂在制备发热伴血小板减少综合征治疗药物中的应用
KR102449653B1 (ko) Kv1.3 칼륨 채널 길항제
Imai et al. Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with crescent formation: an open-label trial to evaluate safety and efficacy
Komlos American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting (ACR Convergence 2020). Virtual-November 5-9, 2020
CA3206197A1 (en) Active delivery of radiotracers across the blood brain barrier
WO2023064373A1 (en) Targeting slc46a2-mediated muropeptide transport to treat psoriasis
EP4351618A2 (en) Trem-2/dap-12 inhibitors for treating lung disease and injury and combinations thereof
ES2267810T3 (es) Tratamiento de la hepatitis c con timosina y peginterferon.
Davis et al. Lack of immune response to mouse IgG in previously untreated haemophilia A and haemophilia B patients treated with monoclonal antibody purified factor VIII and factor IX preparations
Sevransky et al. Anti-inflammatory therapy in sepsis
Masclee et al. Drugs that act on the immune system: cytokines and monoclonal antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150408